Insider Selling: Michael O’hare Unloaded 26,203 Shares of The Estée Lauder Companies Inc. (EL); Haemonetics (HAE)’s Sentiment Is 1.28

The EVP-Global Human Resources of Estee Lauder Companies Inc and firm’s insider Michael O’hare made a sale of 26,203 shares of the New York-based company based on the average stock price of $133.4 for each share. These transaction’s shares are worth approximately $3,495,480 US Dollars. Dated February 5, 2018, this substantial trade by Michael O’hare was revealed in the a public document submitted with the D.C. based-SEC. It is freely available for review here.

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company has market cap of $3.23 billion. The firm operates through five divisions: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It has a 711.63 P/E ratio. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma clients to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.

Investors sentiment decreased to 1.03 in 2017 Q3. Its down 0.18, from 1.21 in 2017Q2. It is negative, as 49 investors sold The Estée Lauder Companies Inc. shares while 211 reduced holdings. 86 funds opened positions while 183 raised stakes. 190.23 million shares or 2.24% less from 194.59 million shares in 2017Q2 were reported. Winslow Evans Crocker Incorporated accumulated 0% or 40 shares. Eaton Vance Mngmt invested in 1.43 million shares or 0.4% of the stock. Parkside Bancorp & Tru accumulated 1,135 shares or 0.05% of the stock. Front Barnett Limited stated it has 71,294 shares or 1.35% of all its holdings. Vontobel Asset Mgmt Incorporated holds 0.22% or 280,932 shares. Glg Prtn Limited Partnership holds 0.13% in The Estée Lauder Companies Inc. (NYSE:EL) or 23,000 shares. Teachers Retirement Sys Of The State Of Kentucky accumulated 114,353 shares or 0.15% of the stock. Convergence Ptnrs Ltd Limited Liability Company stated it has 22,089 shares. Shine Advisory Ser stated it has 0.09% of its portfolio in The Estée Lauder Companies Inc. (NYSE:EL). Donaldson Mgmt Ltd Liability Corp holds 0.28% in The Estée Lauder Companies Inc. (NYSE:EL) or 24,973 shares. Cadence Management Ltd Liability Com owns 4,657 shares. Brown Advisory Inc accumulated 3.84 million shares. 6,821 were reported by Northwestern Mutual Wealth. Investec Asset Limited reported 1.04 million shares. Acadian Asset Mgmt has 0.68% invested in The Estée Lauder Companies Inc. (NYSE:EL) for 1.43 million shares.

Since August 7, 2017, it had 0 insider purchases, and 18 selling transactions for $68.68 million activity. Hockaday Irvine O Jr sold $210,821 worth of stock or 2,000 shares. $284,319 worth of The Estée Lauder Companies Inc. (NYSE:EL) was sold by O’HARE MICHAEL. 2,730 The Estée Lauder Companies Inc. (NYSE:EL) shares with value of $295,135 were sold by Polcer Gregory. $4.13M worth of The Estée Lauder Companies Inc. (NYSE:EL) was sold by Haney Carl P. on Friday, September 1. MOSS SARA E had sold 14,552 shares worth $1.46M on Monday, August 7. Freda Fabrizio sold $31.73M worth of stock. 32,640 shares were sold by FRIBOURG PAUL J, worth $3.47 million.

The stock increased 0.55% or $0.74 during the last trading session, reaching $135.13. About 2.40M shares traded or 48.67% up from the average. The Estée Lauder Companies Inc. (NYSE:EL) has risen 1.49% since February 5, 2017 and is uptrending. It has underperformed by 15.21% the S&P500.

Among 30 analysts covering Estee Lauder (NYSE:EL), 22 have Buy rating, 1 Sell and 7 Hold. Therefore 73% are positive. Estee Lauder has $155.0 highest and $72 lowest target. $122.18’s average target is -9.58% below currents $135.13 stock price. Estee Lauder had 98 analyst reports since July 21, 2015 according to SRatingsIntel. Stifel Nicolaus maintained The Estée Lauder Companies Inc. (NYSE:EL) rating on Monday, September 18. Stifel Nicolaus has “Buy” rating and $114.0 target. The firm has “Buy” rating by Jefferies given on Monday, February 5. The rating was upgraded by Oppenheimer on Thursday, January 26 to “Outperform”. The firm has “Buy” rating by Bank of America given on Friday, October 13. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, December 21. The firm earned “Underperform” rating on Thursday, November 3 by CSLA. UBS maintained The Estée Lauder Companies Inc. (NYSE:EL) rating on Tuesday, November 3. UBS has “Buy” rating and $98 target. The firm has “Buy” rating given on Monday, October 23 by RBC Capital Markets. The firm has “Neutral” rating given on Monday, August 22 by Citigroup. As per Friday, November 3, the company rating was maintained by RBC Capital Markets.

The Estée Lauder Companies Inc. manufactures and markets skin care, makeup, fragrance, and hair care products worldwide. The company has market cap of $49.76 billion. The firm offers a range of skin care products, such as moisturizers, serums, cleansers, toners, body care, exfoliators, acne and oil correctors, facial masks, cleansing devices, and sun care products; and makeup products for face, eyes, lips, and nails, as well as related items, including compacts, brushes, and other makeup tools. It has a 36.51 P/E ratio. It also provides fragrance products in various forms comprising eau de parfum sprays and colognes, lotions, powders, creams, bath/shower products, candles, and soaps; and hair care products consisting of shampoos, conditioners, styling products, treatment, finishing sprays, and hair color products, as well as sells ancillary services and products.

Beaconlight Capital Llc holds 3.06% of its portfolio in Haemonetics Corporation for 129,217 shares. Healthcor Management L.P. owns 1.45 million shares or 2.18% of their US portfolio. Moreover, Rutabaga Capital Management Llc Ma has 2.16% invested in the company for 226,076 shares. The Quebec – Canada-based Van Berkom & Associates Inc. has invested 1.94% in the stock. Adi Capital Management Llc, a New York-based fund reported 73,366 shares.

Ratings analysis reveals 33% of Haemonetics’s analysts are positive. Out of 3 Wall Street analysts rating Haemonetics, 1 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $34.0 while the high is $41.0. The stock’s average target of $37.50 is -38.73% below today’s ($61.2) share price. HAE was included in 3 notes of analysts from September 20, 2016. Barrington Research upgraded the stock to “Outperform” rating in Tuesday, November 8 report. As per Tuesday, September 20, the company rating was downgraded by CJS Securities. Benchmark maintained the shares of HAE in report on Monday, November 7 with “Hold” rating.

The stock decreased 3.55% or $2.25 during the last trading session, reaching $61.2. About 239,049 shares traded. Haemonetics Corporation (HAE) has risen 45.56% since February 5, 2017 and is uptrending. It has outperformed by 28.86% the S&P500.